We are live on ! Find out more
PODD icon

Insulet

787 hedge funds and large institutions have $14.6B invested in Insulet in 2026 Q1 according to their latest regulatory filings, with 88 funds opening new positions, 325 increasing their positions, 269 reducing their positions, and 122 closing their positions.

New
Increased
Maintained
Reduced
Closed

144% more call options, than puts

Call options by funds: $35.7M | Put options by funds: $14.7M

21% more repeat investments, than reductions

Existing positions increased: 325 | Existing positions reduced: 269

1.3% less ownership

Funds ownership: 100.17%98.87% (-1.3%)

6% less funds holding

Funds holding: 834787 (-47)

27% less capital invested

Capital invested by funds: $20B → $14.6B (-$5.4B)

28% less first-time investments, than exits

New positions opened: 88 | Existing positions closed: 122

50% less funds holding in top 10

Funds holding in top 10: 42 (-2)

Holders
787
Holders Change
-47
Holders Change %
-5.64%
% of All Funds
0%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0%
New
88
Increased
325
Reduced
269
Closed
122
Calls
$35.7M
Puts
$14.7M
Net Calls
+$21M
Net Calls Change
+$31.7M

PODD Hedge Fund Activity: Q1 2026 in Review

787 institutional investors reported a position in Insulet (PODD) for Q1 2026, worth a combined $14.6B — down 27% from $20B a quarter earlier.

Sellers outnumbered buyers: 122 funds closed out of PODD and 88 opened new positions — a net loss of 34 holders — while 269 trimmed existing stakes and 325 added.

The largest buyer was T. Rowe Price Investment Management, adding an estimated $456M. The largest seller was Capital Research Global Investors, cutting an estimated $688M.

  • 787 institutional investors held Insulet (PODD) as of Q1 2026, down from 834 in Q4 2025.
  • Funds reported $14.6B of Insulet stock for Q1 2026, down 27% quarter-over-quarter.
  • 88 funds opened new Insulet positions in Q1 2026 and 122 closed out, a net change of -34 holders.
  • The largest Insulet buyer in Q1 2026 was T. Rowe Price Investment Management, an estimated $456M added.
  • The largest Insulet seller in Q1 2026 was Capital Research Global Investors, an estimated $688M sold.

Based on aggregated 13F filings for Q1 2026.